|

Anti-VEGF Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 1

Top Sponsors

  • Shanghai Zhongshan Hospital1
  • Shandong Cancer Hospital and Institute1

Indications

  • Liver Disease2
  • Liver Cancer2
  • Hepatocellular Carcinoma2
  • Cancer2
  • Anti-VEGF Therapy1

Other2 trials

Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
BRAVE Study: QL1706 + Bevacizumab + SBRT for BCLC-C HCC With PVTT or Oligometastases
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.